Actively Recruiting

Phase Not Applicable
Age: 18Years - 70Years
All Genders
NCT06826937

Short-Term Recall and Reprocess Therapy for Post Traumatic Stress Disorder (PTSD)

Led by Ben-Gurion University of the Negev · Updated on 2025-02-14

160

Participants Needed

1

Research Sites

309 weeks

Total Duration

On this page

Sponsors

B

Ben-Gurion University of the Negev

Lead Sponsor

S

Soroka University Medical Center

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical trial is to learn if a short-term behavioral intervention, based on imaginal and in-vivo exposure and psychodynamic reprocessing, works on alleviating Post-Traumatic Stress Disorder (PTSD) symptoms in adults. The trial will also learn about patterns of recovery and relapse by following the patients for up to five years. The main questions it aims to answer are: Does the reconsolidation-based short-term intervention help alleviate PTSD symptoms? How is it affecting other mental health issues (such as depression, sleep problems, and general functioning)? What is the long-term effect of the intervention? Researchers will compare this behavioral intervention to a waiting list, for up to three months. People on the waiting list will then be able to cross over to the treatment arm as well. Participants will: Be screened by a clinical psychologist Take the week-long intensive behavioral intervention (psychotherapy) Followed at the end of treatment (day 7), at 30 and 90 days, and every 6 months, up to five years. Wearable devices will be used during the week before treatment, during treatment, and up to 30 days following the end of treatment.

CONDITIONS

Official Title

Short-Term Recall and Reprocess Therapy for Post Traumatic Stress Disorder (PTSD)

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of PTSD with a score of 25 or higher on the Clinician-Administered PTSD Scale (CAPS-5) at screening
  • Stable treatment for at least 4 weeks with FDA-approved antidepressants, trazodone, atypical neuroleptics, prazosin, or clonidine if applicable
  • Able to provide written informed consent
  • Able to read and write English or Hebrew
  • Age between 18 and 70 years
Not Eligible

You will not qualify if you...

  • Diagnosis or history of bipolar disorder, borderline personality disorder, obsessive-compulsive disorder, schizophrenia, schizoaffective disorder, or current psychotic features
  • Dementia or suspicion of dementia
  • History of antidepressant-induced hypomania or mania
  • Current serious suicidal risk
  • Moderate or greater substance use disorder (except alcohol) within 3 months prior to randomization
  • History of traumatic brain injury with loss of consciousness over 24 hours or amnesia over 7 days within the past year
  • Significant neurological illness or heart disease
  • Signs of major medical or neurological illness from examination, ECG, or lab studies
  • History of learning disability or mental retardation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Ben Gurion University of the Negev

Beersheba, Israel, 8410501

Actively Recruiting

Loading map...

Research Team

O

Or Duek, Ph.D

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here